$CGTX News

Cognition Therapeutics: Clearer FDA Path, But Potential Dilution Risks Remain

FDA Agrees Psychosis Associated With Dementia With Lewy Bodies May Be Approvable Outcome, Reaches Alignment With Cognition Therapeutics On Vital Aspects To Support Its New Drug Application

Cognition Therapeutics Receives Notice Of Allowance From USPTO For Patent Application 19/563,468, Covering Polymorphic Crystalline Form Of Zervimesine

Cognition Therapeutics Announces Second Philanthropic Donation From A Participant In The Ongoing Expanded Access Program For People With Dementia With Lewy Bodies

Cognition Therapeutics To Update On Progress Of Its Development Programs For Alzheimer's Disease And Dementia With Lewy Bodies At 25th Annual Needham Virtual Healthcare Conference

Cognition Therapeutics CEO Issues Letter to Shareholders

Cognition Therapeutics shares are trading lower. The company reported Q4 financial results.

Cognition Therapeutics shares are trading lower. The company reported Q4 financial results.

Cognition Therapeutics Inc (CGTX) Q4 2025 Earnings Call Highlights: Promising Developments in ...

Cognition Therapeutics Q4 Earnings Call Highlights

Cognition Therapeutics (NASDAQ:CGTX) Narrows Loss, Eyes Key FDA Meeting on DLB Drug

Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update

Cognition Therapeutics, Inc. (CGTX) Q4 2025 Earnings Call Transcript

Cognition Therapeutics Q4 EPS $(0.01) Beats $(0.05) Estimate

Cognition Therapeutics Presents Analysis From Phase 2 COG1201 SHIMMER Study Of Zervimesine In Dementia With Lewy Bodies At AD/PD 2026 Alzheimer's & Parkinson's Diseases Conference

Cognition Positions Zervimesine For Potential Expedited Path In DLB Psychosis, Highlighting Favorable Neuropsychiatric And Motor Profile In Phase 2

Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

Cognition Therapeutics Extends Duration Of Expanded Access Program For Dementia With Lewy Bodies

Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies

Cognition Therapeutics Meets With FDA to Plan Mid-Stage Trial for Lewy Body Dementia Drug